AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
AbbVie (NYSE: ABBV) and Simcere Zaiming have announced a partnership to develop SIM0500, a novel trispecific antibody for multiple myeloma. The drug candidate, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 using Simcere's T-cell engager polyspecific antibody technology platform.
The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential option fees and milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within the Greater China territory. SIM0500 has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.
AbbVie (NYSE: ABBV) e Simcere Zaiming hanno annunciato una partnership per sviluppare SIM0500, un nuovo anticorpo trispecifico per il mieloma multiplo. Il candidato farmaco, attualmente in fase 1 di sperimentazione clinica in Cina e negli Stati Uniti, colpisce GPRC5D, BCMA e CD3 utilizzando la piattaforma tecnologica di anticorpi polyspecifici T-cell engager di Simcere.
L'accordo include un pagamento iniziale da parte di AbbVie a Simcere Zaiming, con potenziali commissioni opzionali e pagamenti legati a tappe che potrebbero raggiungere fino a 1,055 miliardi di dollari, oltre a royalties scaglionate sulle vendite nette al di fuori della Grande Cina. AbbVie riceverà royalties scaglionate sulle vendite all'interno del territorio della Grande Cina. SIM0500 ha dimostrato una forte citotossicità delle cellule T contro le cellule del mieloma multiplo attraverso vari effetti antitumorali.
AbbVie (NYSE: ABBV) y Simcere Zaiming han anunciado una asociación para desarrollar SIM0500, un nuevo anticuerpo trispecífico para mieloma múltiple. El candidato a medicamento, actualmente en ensayos clínicos de Fase 1 en China y en EE. UU., tiene como objetivo GPRC5D, BCMA y CD3 utilizando la plataforma tecnológica de anticuerpos polispecíficos T-cell engager de Simcere.
El acuerdo incluye un pago inicial de AbbVie a Simcere Zaiming, con potenciales tarifas opcionales y pagos por hitos que podrían alcanzar hasta 1.055 mil millones de dólares, además de regalías escalonadas sobre las ventas netas fuera de la Gran China. AbbVie recibirá regalías escalonadas por las ventas dentro del territorio de la Gran China. SIM0500 ha demostrado una fuerte citotoxicidad de células T contra células de mieloma múltiple a través de varios efectos antitumorales.
AbbVie (NYSE: ABBV)와 Simcere Zaiming이 다발성 골수종에 대한 새로운 삼특이 항체인 SIM0500을 개발하기 위해 파트너십을 발표했습니다. 현재 중국과 미국에서 1상 임상 시험 중인 이 약물 후보는 Simcere의 T세포 결합 다특이 항체 기술 플랫폼을 사용하여 GPRC5D, BCMA 및 CD3를 타겟으로 합니다.
이 계약에는 AbbVie가 Simcere Zaiming에 선불금을 지급하는 내용이 포함되어 있으며, 선택적 수수료와 이정표 지급금이 최대 10억 5500만 달러에 이를 수 있으며, 대중화 지역 외의 순매출에 대해 단계별 로열티가 추가됩니다. AbbVie는 대중화 지역 내 판매에 대해 단계별 로열티를 받게 됩니다. SIM0500은 다양한 항종양 효과를 통해 다발성 골수종 세포에 대한 강력한 T세포 세포독성을 입증했습니다.
AbbVie (NYSE: ABBV) et Simcere Zaiming ont annoncé un partenariat pour développer SIM0500, un anticorps trispecifique novateur pour le myélome multiple. Le candidat médicament, actuellement en phase 1 d'essais cliniques en Chine et aux États-Unis, cible GPRC5D, BCMA et CD3 grâce à la plateforme technologique d'anticorps polyspecifiques T-cell engager de Simcere.
Le contrat comprend un paiement initial de la part d'AbbVie à Simcere Zaiming, avec des frais d'option potentiels et des paiements d'étape pouvant atteindre jusqu'à 1,055 milliard de dollars, plus des redevances échelonnées sur les ventes nettes hors de la Grande Chine. AbbVie recevra des redevances échelonnées sur les ventes dans le territoire de la Grande Chine. SIM0500 a montré une forte cytotoxicité des cellules T contre les cellules de myélome multiple grâce à divers effets antitumoraux.
AbbVie (NYSE: ABBV) und Simcere Zaiming haben eine Partnerschaft bekannt gegeben, um SIM0500, einen neuartigen trispezifischen Antikörper gegen multiples Myelom, zu entwickeln. Der Arzneimittelkandidat, der sich derzeit in Phase 1 klinischer Studien in China und den USA befindet, zielt auf GPRC5D, BCMA und CD3 ab und nutzt Simceres polyspezifische Antikörper-Technologie zur T-Zell-Aktivierung.
Die Vereinbarung umfasst eine Vorauszahlung von AbbVie an Simcere Zaiming, mit potenziellen Optionsgebühren und Meilensteinzahlungen, die bis zu 1,055 Milliarden Dollar erreichen könnten, sowie gestaffelte Lizenzgebühren auf Nettoumsätze außerhalb von Greater China. AbbVie wird gestaffelte Lizenzgebühren auf Verkäufe im Gebiet Greater China erhalten. SIM0500 hat eine starke zytotoxische Wirkung auf T-Zellen gegen multiple Myelomzellen durch verschiedene antitumorale Effekte gezeigt.
- Potential milestone payments and option fees worth up to $1.055B
- Additional revenue stream through tiered royalties from Greater China market
- Phase 1 clinical trials already ongoing in both U.S. and China markets
- Early-stage drug candidate with uncertain clinical success
- Royalty payments to Simcere will impact profit margins outside Greater China
Insights
This strategic partnership marks a significant advancement in multiple myeloma treatment development. The SIM0500 trispecific antibody represents cutting-edge immunotherapy technology, targeting three distinct proteins (GPRC5D, BCMA and CD3) simultaneously. The dual-targeting of GPRC5D and BCMA is particularly innovative, as it could potentially reduce the likelihood of cancer resistance and treatment escape mechanisms commonly seen with single-target therapies.
The deal structure, featuring an upfront payment plus
The molecular design of SIM0500 is particularly noteworthy. The low affinity/high target-activating CD3 engaging arm is engineered to optimize the balance between efficacy and safety, potentially reducing cytokine release syndrome - a common concern with T-cell engaging therapies. The dual targeting of GPRC5D and BCMA is significant because BCMA-targeted therapies have shown promising results but often face resistance, while GPRC5D is an emerging target that has demonstrated effectiveness in early clinical studies.
The ongoing Phase 1 trials in both China and the U.S. suggest a well-planned clinical development strategy. For non-technical readers, think of this drug as a "triple-threat" approach - it's like having three different tools working together to fight cancer cells, potentially making it harder for the cancer to develop resistance to the treatment.
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.
"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma"
"SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. "
Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in
View original content:https://www.prnewswire.com/news-releases/abbvie-and-simcere-zaiming-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma-302348650.html
SOURCE AbbVie
FAQ
What is the potential value of AbbVie's (ABBV) deal with Simcere Zaiming?
What type of drug is SIM0500 and what does it target?
What stage of development is ABBV's SIM0500 currently in?
How will the royalty structure work in the ABBV-Simcere partnership?
What technology platform was used to develop ABBV's new multiple myeloma drug?
